First head-to-head trial to show #PsA joint outcome superiority
BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%.
@RheumNow #EULAR2026 LB0001
https://x.com/JihaRheum/status/2063218845842571488/photo/1
BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%.
@RheumNow #EULAR2026 LB0001
